Clinical Trial Update: Efficacy, Tolerability and Safety of LAS41004 Formulations in a Psoriasis Plaque Test [Phase 1, Phase 2]

View source ↗

Summary

This trial update reports on the efficacy, tolerability, and safety of LAS41004 formulations in a psoriasis plaque test across Phase 1 and Phase 2.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis

Drugs mentioned

• LAS41004

Snippet

Sponsor: Almirall, S.A. | Conditions: Psoriasis | Phase 1, Phase 2 | Status: COMPLETED